公开(公告)号：US10550369B2

公开(公告)日：2020-02-04

申请号：US15945148

申请日：2018-04-04

Applicant: Mesoblast International Sárl

Inventor： Samson Tom ,  Christopher Ton ,  Alla Danilkovitch

IPC: A61K35/28 ,  C12N5/0775 ,  A61K41/00 ,  A61K49/04 ,  A61K49/18 ,  B82Y5/00 ,  A61K47/69 ,  A61M37/00

Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

公开(公告)号：US08852573B2

公开(公告)日：2014-10-07

申请号：US13370034

申请日：2012-02-09

Applicant: Mark F. Pittenger ,  Stephen L. Gordon ,  Alastair Morgan Mackay

Inventor： Mark F. Pittenger ,  Stephen L. Gordon ,  Alastair Morgan Mackay

IPC: A61K48/00 ,  C12N15/85

CPC classification number: A61K35/28 ,  A61K35/12 ,  A61K48/00 ,  A61K2035/124 ,  C12N5/0657 ,  C12N5/0663 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2510/02 ,  C12N2533/54

Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

公开(公告)号：US08852572B2

公开(公告)日：2014-10-07

申请号：US13370009

申请日：2012-02-09

Applicant: Mark F. Pittenger ,  Stephen L. Gordon ,  Alastair Morgan Mackay

Inventor： Mark F. Pittenger ,  Stephen L. Gordon ,  Alastair Morgan Mackay

IPC: A61K48/00 ,  C12N15/85

CPC classification number: A61K35/28 ,  A61K35/12 ,  A61K48/00 ,  A61K2035/124 ,  C12N5/0657 ,  C12N5/0663 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2510/02 ,  C12N2533/54

Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

公开(公告)号：US20140161776A1

公开(公告)日：2014-06-12

申请号：US14138577

申请日：2013-12-23

Applicant: Mesoblast International Sarl

Inventor： Sudeepta Aggarwal ,  Mark F. Pittenger ,  Timothy Varney

IPC: A61K35/28

Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Abstract translation: 通过以有效量施用人间充质干细胞来促进人的伤口愈合的组合物和方法。

公开(公告)号：US08637004B2

公开(公告)日：2014-01-28

申请号：US12541282

申请日：2009-08-14

Applicant: Alla Danilkovich ,  Robert E. Newman, Jr. ,  Samson Tom ,  Christopher Ton ,  Zhanling Wang ,  Randell G. Young

Inventor： Alla Danilkovich ,  Robert E. Newman, Jr. ,  Samson Tom ,  Christopher Ton ,  Zhanling Wang ,  Randell G. Young

IPC: C12N5/00

CPC classification number: A61K35/28 ,  A61K2035/124 ,  C12N5/0663

Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

Abstract translation: 公开了一种或多种纯化的间充质干细胞药物组合物和利用离心过滤的制备方法。 还公开了静脉内施用包含残留动物产物的间充质干细胞药物组合物的阈限。

公开(公告)号：US20230141347A1

公开(公告)日：2023-05-11

申请号：US17870936

申请日：2022-07-22

Applicant: Mesoblast International Sarl

Inventor： Silviu Itescu ,  Paul Simmons

IPC: A61K35/28 ,  A61K35/545 ,  A61K38/17 ,  A61P29/00 ,  A61P3/10 ,  A61K9/00 ,  A61K38/18

CPC classification number: A61K35/28 ,  A61K35/545 ,  A61K38/17 ,  A61P29/00 ,  A61P3/10 ,  A61K9/0019 ,  A61K38/18

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

公开(公告)号：US20230124294A1

公开(公告)日：2023-04-20

申请号：US17964905

申请日：2022-10-12

Applicant: Mesoblast International Sarl

Inventor： Silviu Itescu ,  Lee Golden

IPC: A61K35/28 ,  C12N5/0775

Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.

公开(公告)号：US11406669B2

公开(公告)日：2022-08-09

申请号：US16828121

申请日：2020-03-24

Applicant: Mesoblast International Sarl

Inventor： Silviu Itescu ,  Paul Simmons

IPC: A61K35/28 ,  A61K35/545 ,  A61P29/00 ,  A61P3/10 ,  A61K38/17 ,  A61K9/00 ,  A61K38/18

Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

公开(公告)号：US20210388319A1

公开(公告)日：2021-12-16

申请号：US17286972

申请日：2019-10-31

Applicant: Mesoblast International Sarl

Inventor： Silviu Itescu ,  Paul Simmons

IPC: C12N5/0789 ,  A61K35/28

Abstract: The present disclosure relates to methods and compositions for expansion of human hematopoietic stem cells. The present disclosure also relates to methods of treatment involving the use of the expanded HSCs.

公开(公告)号：US20140112893A1

公开(公告)日：2014-04-24

申请号：US14138265

申请日：2013-12-23

Applicant: Mesoblast International Sarl

Inventor： Samson Tom ,  Christopher Ton ,  Alla Danilkovitch

IPC: C12N5/0775

CPC classification number: C12N5/0663 ,  A61K35/28 ,  A61K41/0038 ,  A61K41/0052 ,  A61K47/6901 ,  A61K49/0423 ,  A61K49/1827 ,  A61M37/00 ,  B82Y5/00 ,  C12N2511/00

Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Abstract translation: 本发明提供具有重要治疗潜力的MSC的制备。 MSC细胞是具有小于约1.25％CD45 +细胞（或小于约0.75％CD45 +），至少约95％CD105 +细胞和至少约95％CD166 +细胞的抗原谱的非原代细胞。 任选地，本制剂的MSC是同基因的，并且可以离体扩增并冷冻保存和解冻，但保持稳定和均匀的表型。 在这里教授扩展这些MSC以产生临床量表治疗制剂及其医疗用途的方法。